Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia.

Cancer Res. 1985 Sep;45(9 Suppl):4559s-4562s. Unique Identifier : AIDSLINE MED/85254470
Waldmann TA; Longo DL; Leonard WJ; Depper JM; Thompson CB; Kronke M; Goldman CK; Sharrow S; Bongiovanni K; Greene WC


Abstract: Interleukin-2 (IL-2) is a lymphokine synthesized by some T-cells following activation. Resting T-cells do not express IL-2 receptors, but receptors are rapidly expressed on T-cells following interaction of antigens, mitogens, or monoclonal antibodies with the antigen-specific T-cell receptor complex. Using anti-Tac, a monoclonal antibody that recognizes the IL-2 receptor, the receptor has been purified and shown to be a Mr 33,000 peptide that is posttranslationally glycosylated to a Mr 55,000 mature form. Normal resting T-cells and most leukemic T-cell populations do not express IL-2 receptors; however, the leukemic cells of the 11 patients examined who had human T-cell lymphotropic virus-associated adult T-cell leukemia expressed the Tac antigen. In human T-cell lymphotropic virus-I infected cells, the Mr 42,000 long open reading frame protein encoded in part by the pX region of this virus may act as a transacting transcriptional activator that induces IL-2 receptor gene transcription, thus providing an explanation for the constant association of IL-2 receptor expression with adult T-cell lymphotropic virus-I infection of lymphoid cells. The constant expression of large numbers of IL-2 receptors which may be aberrant may play a role in the uncontrolled growth of adult T-cell leukemia cells. Two patients with Tac-positive adult T-cell leukemia have been treated with the anti-Tac. One of the patients had 6- and 3-mo remissions of his leukemia following two courses of therapy with this monoclonal antibody directed toward this growth factor receptor.
Keywords: Adult Antibodies, Monoclonal/THERAPEUTIC USE Cell Line Genes, Viral Human *HTLV-BLV Viruses/GENETICS Leukemia/BLOOD/*MICROBIOLOGY/THERAPY Lymphocyte Transformation Male Receptors, Immunologic/ANALYSIS/*BIOSYNTHESIS/IMMUNOLOGY/ ISOLATION & PURIF Retroviridae Infections/BLOOD/MICROBIOLOGY T-Lymphocytes/*METABOLISM/MICROBIOLOGY Transcription Factors Transcription, Genetic Viral Proteins/GENETICS/PHYSIOLOGY JOURNAL ARTICLE

KWDadultantibodies,monoclonal/therapeuticusecelllinegenes,viralhumanKWDhtlv-blvviruses/geneticsleukemia/blood/KWDmicrobiology/therapylymphocytetransformationmalereceptors,immunologic/analysis/KWDbiosynthesis/immunology/isolation&purifretroviridaeinfections/blood/microbiologyt-lymphocytes/KWDmetabolism/microbiologytranscriptionfactorstranscription,geneticviralproteins/genetics/physiologyjournalarticle
851130
M85B0118


Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .